Elanco Expects Reduction Of Approximately $5M - $10M Of Adjusted EBITDA In 2024 Related To TriRx Situation
Portfolio Pulse from Benzinga Newsdesk
Elanco anticipates a reduction in adjusted EBITDA by $5M to $10M in 2024 due to the TriRx situation. However, the company still expects to meet its full-year adjusted EBITDA guidance of $900M to $940M.
September 13, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elanco expects a $5M-$10M reduction in adjusted EBITDA for 2024 due to the TriRx situation but maintains its full-year guidance of $900M-$940M.
The news indicates a potential financial impact on Elanco due to the TriRx situation, but the company reassures investors by maintaining its full-year EBITDA guidance. This suggests that while there is a negative impact, it is not significant enough to alter overall expectations, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100